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ABSTRACT

Activation of Ca2+ –Activated K+ Channels and Cell Migration by Hepatocyte Growth
Factor/Scatter Factor in Madin-Darby Canine Kidney Cells
by
Min Jin

Hepatocyte Growth Factor/Scatter Factor (HGF/SF) stimulates migration of various cells and has
been linked via Met tyrosine kinase signaling to transformation and the metastatic phenotype.
HGF/SF–Met signaling also plays a role in malignancy. Migration of transformed MDCK-F
cells depends on activation of a charybdotoxin (ChTX)-sensitive, volume-activated membrane
K+ current. Patch-clamp electrophysiology and transwell migration assays were used to study
the effects of HGF/SF on membrane K+ currents and cell migration in MDCK II cells. HGF/SF
activated membrane K+ currents that increased over 24 hr, and these could be modulated by
altering intracellular free calcium concentration [Ca2+]i. HGF/SF also significantly increased
MDCK II cell migration. Specific Ca2+–activated K+ channel blockers, ChTX, iberiotoxin
(IbTX), stichodactyla toxin (Stk) and clotrimazole (CLT) inhibited HGF/SF stimulation of
membrane K+ currents and cell migration. This suggests that the activation of Ca2+-activated K+
channels is necessary for HGF/SF stimulation of MDCK II cell migration. Furthermore,
HGF/SF induced ERK phosphorylation, and addition of the MEK inhibitor PD98059 inhibited
ERK phosphorylation, as well as HGF/SF stimulation of Ca2+-activated K+ currents and cell
migration in MDCK II cells. Taken together, HGF/SF induces phosphorylation of ERK, which
plays a role in HGF/SF activation of Ca2+-activated K+ channels and enhancing cell migration in
MDCK II cells.
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CHAPTER 1
INTRODUCTION

HGF/SF
Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional effector of cells
expressing the Met tyrosine kinase receptor. HGF/SF was the first member of the plasminogenrelated growth factor family, which resembles blood protease plasminogen in structure and
mechanism of activation. Macrophage-stimulating protein (MSP) is the other member identified
in this family so far. Expression of the HGF/SF gene is restricted to fibroblasts and other
mesenchymal cells; whereas, expression of the c-Met gene is confined to cells that do not secrete
the ligand.
Inactive precursor of HGF/SF (proHGF/SF) is a single-chain peptide of 728 amino acids.
Biologically active HGF/SF is produced by proteolytic cleavage of proHGF/SF between R494 and
V495. Mutations of R494 generate an uncleavable HGF/SF, which can bind to HGF/SF receptor
but cannot induce receptor phosphorylation (Hartmann et al. 1992). There is evidence that
urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA) can convert
proHGF/SF into the mature HGF/SF. Biologically active HGF/SF is a αβ heterodimer held
together by a disulfide bond. The larger α subunit (60 kDa) contains an N-terminal hairpin loop
homologous to the activation peptide of plasminogen and four kringle domains which are triplelooped cysteine-rich motifs involved in protein-protein interaction. The smaller β subunit (34
kDa) resembles the catalytic domain of serine proteases (Birchmeier and Gherardi 1998).
Fig.1A shows the schematic structure of HGF/SF. Studies on HGF/SF variants using
progressive deletions and point mutations have mapped the receptor binding site within the first
kringle and identified two groups of amino acids, E159, S161, E195, R197 and D171, Q173, which
appear to be essential for receptor binding (Lokker et al. 1992).
13

HGF/SF Receptor, Met
HGF/SF receptor, Met, was originally isolated as the product of a human oncogene, tprmet, which encodes an altered Met protein possessing constitutive, ligand-independent tyrosine
kinase activity and transforming ability (Zhen et al. 1994). Met is a prototype of a tyrosine
kinase family including the receptors encoded by the oncogenes RON and SEA. Met is a dimeric
transmembrane polypeptide cleaved from a single polypeptide chain upon secretion. This
receptor comprises an N-terminal α chain (50 kDa) exposed at the cell surface and a C-terminal
β chain (145 kDa) spanning the plasma membrane. The heavily glycosylated α chain is disulfide
linked to β chain. The β chain contains the tyrosine kinase (TK) domain, the tyrosine
autophosphorylation sites and the multidocking site. The activation of the signal transduction
downstream of Met is through the multidocking site, which comprises a short amino acid
sequence motif (YVNVXXXYVHV) located near the C-terminus of the β chain. Two tyrosine
residues (Y1349 and Y1356) are located within the multidocking site and are phosphorylated
upon ligand binding. Mutations of these tyrosine residues can abolish all receptor activity in
vitro and in vivo (Park and Hayman 1999). Both α and β chains of Met are required for highaffinity binding of HGF/SF. HGF/SF binding to Met induces receptor dimerization and
phosphorylation of the Met receptor. Upon Met activation, multiple SH2 (Src homology region
2)-containing intracellular signal transducers and adaptor molecules bind to the phosphorylated
tyrosine residues within the multidocking site, and the phosphorylation of these molecules
results in the activation of down stream cascade, Fig. 1B. Several of the known transducers are
Ras, p85 subunit of PI 3-kinase, PLC-γ, Src-related tyrosine kinase, Grb-2 adaptor for SOS and
Gab-1, an IRS-like multiadaptor protein, and a novel SH2-domain-containing inositol
5phosphotase (SHIP)-1 (Ponzetto et al. 1994; Weidner et al. 1996; Stefan et al. 2000). Recent in
vitro studies have shown that cell motility response to HGF/SF requires the activation of both PI
3-kinase and Ras pathways (Ridley et al. 1995; Sachs et al. 1996), whereas Ras-MAPK pathway
14

through the Grb-SOS complex is necessary and sufficient for cell proliferation (Ponzetto et al.
1996).
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Figure 1 Schematic model of the proteolytic cleavage from proHGF/SF to HGF/SF and the Met
dimerization and activation upon HGF/SF binding. A. Schematic model of the proteolytic
cleavage from proHGF/SF to biologically active HGF/SF. The larger α subunit contains an Nterminal hairpin loop and four kringle domains. The smaller β subunit resembles the catalytic
domain of serine proteases. B. Schematic representation of Met dimerization and activation
upon HGF/SF binding, and the main signaling molecules. The two phosphorylated tyrosines of
the multidocking site (Y*) are shown (see text for detailed description).
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Biological Activities of HGF/SF and Met
HGF/SF is secreted by mensenchymal cells, and it functions mainly through a paracrine
mechanism on various cells expressing c-Met. HGF/SF is essential for normal embryological
development of the nervous system, kidney, muscle, mammary gland, and liver because it plays
a role in conversion from mesenchyme to epithelium (Matsumoto and Nakamura 1996, 1997). A
germline point mutation in the multidocking site of c-Met causes a semi-lethal phenotype in
mice, the newborns die from inefficient breathing, sucking and forelimb extension. This
phenotype is due to the deficient migration of myoblast precursors from the cervical somites,
resulting in the muscles of diaphragm, tongue, and forelimbs being underdeveloped. Full knock
out mice die in utero from severe defects in liver and placenta. There also is evidence of an
underdeveloped nervous system in the knock out mice; the sensory nerves in both limbs and
thorax are severely reduced, revealing the role of HGF/SF-Met signaling in axonal development
and survival (Maina et al. 1996; Stella and Comoglio 1999).
HGF/SF-Met signaling mediates various normal cellular processes in target cells, such as
inducing cell proliferation, motility, morphological changes, and matrix invasion (Matsumoto
and Nakamura 1996, 1997; Montesano et al. 1997). In addition to stimulating epithelial cell
growth and survival, HGF/SF is a strong angiogenic factor for endothelial cells both in vivo and
in vitro. HGF/SF also acts as an anti-apoptotic factor. Furthermore, HGF/SF is involved in bone
remodeling that requires a tight coupling between osteoclasts and osteoblasts. HGF/SF is
secreted by osteoclasts and binds to its receptors both on osteoclasts and osteoblasts. Secreted
by monocytes and their precursors, HGF/SF induces erythroid hematopoietic precursors to grow
and differentiate, thus stimulating the erythroid colonies (BFU) in blood (Stella and Comoglio
1999). HGF/SF signaling also is involved in the processes of tissue regeneration and wound
healing (Matsumoto and Nakamura 1997).
This receptor-ligand pair also plays a role in malignancy. The coexpression of unaltered
Met and HGF/SF molecules in the same cell, which generates an autocrine stimulatory loop, is
16

also oncogenic. Elevated levels of HGF/SF and/or over-expression of Met receptors are found in
various types of tumors. HGF/SF-Met signaling has been shown to enhance the in vitro
invasiveness and in vivo metastatic potential of tumor cells, such as ras-transformed NIH3T3,
C127, and SK-LMS-1 cells (Jeffers et al. 1996; Jeffers et al. 1996a, 1996b).
Multiple signaling pathways downstream of HGF/SF-Met are involved in HGF/SF
stimulation of cell migration and metastasis in various cell types. It has been shown that
HGF/SF promotes cell invasion by increasing integrin avidity through Ras activation (Trusolino
et al. 2000). PI 3-kinase activation stimulated by HGF/SF induces redistribution of junctional
complex proteins, such as E-cadherin, desmoplakins and ZO-1, which in turn induces cell
dissociation and scattering (Royal and Park 1995; Khwaja et al. 1998). HGF/SF also induces
actin cytoskeleton remodeling, cell spreading and dissociation by activating Rho GTPase, PAK
and Rho-kinase (Royal and Park 1995; Royal et al. 2000). PAK activity, through
phosphorylation and inhibition of myosin light chain kinase (MLCK), promotes a decrease in
actin-myosin filament assembly, allowing remodeling of actin cytoskeleton to form a
lamellipodium (Royal and Park 1995; Sanders et al. 1999).
Furthermore, it is shown that HGF/SF can affect ion transport in normal and malignant
cell types. HGF/SF-induced Ca2+ oscillation is observed in primary cultured rat hepatocytes
(Kawanishi et al. 1995). It is also shown that HGF/SF induces sustained elevation of [Ca2+]i in
rat ovarian surface epithelial cells in part by its ability to decrease cell contact, since homophilic
N-cadherin binding between adhering cells plays an important role in maintaining Ca2+
homeostasis (Gulati and Peluso 1997; Peluso 1997). HGF/SF induces an oscillatory Ca2+activated K+ current in human gastric carcinoma SC-M1 cells, which is abolished when
tetraethyl-ammonium chloride or a low Ca2+ solution is included in the recording pipette (Liu et
al. 1998).
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Therapeutic Applications of HGF/SF and Met
HGF/SF expression is up regulated in liver injury and induces liver proliferation and
regeneration. It has been shown that HGF/SF can recover hepatocytes from hyperaccumulation
of lipids, preventing the onset of pathological ‘fatty liver’ (Tahara et al. 1999). It is also shown
that HGF/SF gene therapy may prevent the cirrhotic liver (Ueki et al. 1999). HGF/SF stimulates
compensatory growth in the remaining kidney in nephrectomized rats. This renotrophic function
of HGF/SF has been used to prevent renal failure following cisplatin treatment (Kawaida et al.
1994).
HGF/SF-Met signaling plays an important role in tumor growth and metastasis, which
has drawn attention to develop drugs for cancer treatment. The intervention of HGF/SF-Met
signaling inhibits cell invasiveness in vitro as well as tumor growth and metastasis in vivo in
some tumors (Cao et al. 2001; Furge et al. 2001). Neutralizing monoclonal antibodies to
HGF/SF used in this study has been shown to inhibit HGF/SF stimulation of scattering in MDCK
cells and branching morphogenesis in SK-LMS-1 cells via blocking HGF/SF-Met signaling;
more importantly, they also inhibit the growth of human glioblastoma multiforme xenografts in
athymic nu/nu mice (Cao et al. 2001).
Recently, attempts have been made to engineer HGF/SF variants for cancer therapy. An
HGF/SF MSP (macrophage-stimulating protein) chimera, Metron factor 1, prevents apotosis and
stimulates cell proliferation but is devoid of pro-invasive activity of HGF/SF (Michieli et al.
2002). HGF/NK4, a four-kringle competetive antagonist of HGF/SF, inhibits angiogenesis, as
well as tumor growth and metastasis in mice (Kuba et al. 2000). Therefore, HGF/SF is a
promising candidate for therapies of organ regeneration, as well as cancer.

Cell Migration
Migration plays an important role in wound healing, tumor metastasis, and many other
biological activities of various cells. Cell volume changes and actin cytoskeletal machinery
18

underlie cell migration. Migration involves substantial reorganization of the cytoskeleton both at
the leading edge and the rear of the migrating cell. At the leading edge (lamellipodia or
filopodia), polymerization of actin filaments prevails, resulting in the protrusion of lamellipodia
or filopodia; whereas at the rear of the cells, actin filaments are depolymerized. The
depolymerization is mediated by capping or escort proteins such as gelsolin, which are
stimulated by Ca2+ (Stossel 1993; Witke et al. 1995). Bound to the capping or escort proteins,
the actin monomers travel toward the leading edge, where they are reutilized for elongation of
the actin filaments. At the rear of the cell, local cell swelling tends to occur because of actin
depolymerization; however, regulatory volume decrease (RVD) and Ca2+ stimulus at the rear of
the cell overcomes the effect of actin depolymerization, resulting in local osmotic shrinkage.
Whereas, local osmotic swelling occurs at the leading edge of the cell as the regulatory volume
increase (RVI) counteracts the effect of actin polymerization at the lamellipodium. Thus,
polymerization at the leading edge and depolymerization at the rear of the cells contribute to the
local volume changes that also facilitate cell migration (Lang et al. 1998). The matrix also exerts
an opposite traction force on the migrating cell through cell-matrix attachment. Therefore, the
protrusion of lamellipodia, contraction in the cell body, and cell-matrix interaction all play a role
in cell migration.
It has been proposed that ion channels and transporters modulate cytoskeletal migration
machinery by regulating [Ca2+]i and local cell volume in migrating cells (Schwab 2001). [Ca2+]i
oscillation in the rear of the cell activates Ca2+-activated K+ channels, which results in local
regulatory cell volume decrease (RVD) and promotes the retraction of a migrating cell. [Ca2+]i is
also an important regulator for cytoskeletal proteins, it plays a role in triggering actin
depolymerization in the rear end of migrating cells. In contrast, low [Ca2+]i in the front favors
the protrusion of lamellipodium. Blocking Ca2+ channels decreases the rate of migration in
granule cells (Komuro and Rakic 1998). At the lamellipodium, Na+/H+ and Na+-K+-2Clcotransporters favors local regulatory cell volume increase (RVI). Inhibition of Na+-K+-2Cl19

cotransporter or Ca2+-activated K+ channels prevents volume fluctuation and inhibits migration
of alkali-transformed MDCK-F cells (Schwab et al. 1994). Glioma cell migration is inhibited by
Cl- and K+ channel blockers such as chlorotoxin, tetraethylammonium chloride, and tamoxifen
(Soroceanu et al. 1999). There is evidence that differentiated intestinal epithelial cells after
wounding exhibit increased migration partially by increasing voltage-gated K+ channel activity
and elevation of cytosolic free Ca2+ concentration (Rao et al. 2002).

MDCK-F Cells and K+ channels
MDCK epithelial cells grow in colonies of tightly associated cells and have been used as
an in vitro model for HGF/SF-induced scattering, migration, and tubulogenesis (Terauchi and
Kitamura, 2000). Prolonged exposure to an alkaline culture medium transforms MDCK, which
dramatically affects cell function and polarization (Schwab and Oberleithner 1996). Alkalinetransformed MDCK-F cells proliferate and migrate without contact inhibition, they also show
remarkably altered electrophysiological properties, such as fluctuations of intracellular Ca2+
activity, membrane conductance and membrane potential (Schwab et al. 1995; Schwab and
Oberleithner 1996). Ca2+- activated K+ channels underlie the oscillation of the membrane
potential. Application of K+ channel blockers, such as barium, tetraethylammonium, 4aminopyridine, and charybdotoxin markedly inhibits cell migration, pointing to the importance
of K+ channels in this process (Schwab et al. 1994). Schwab et al. have demonstrated that the
intermediate conductance Ca2+-activated K+ channel, IK, modulates the migration of the
alkaline-transformed MDCK-F cells by local volume regulation (Schwab et al. 1994).

MAPK Signaling Pathway
It has been shown that MEK inhibitor PD98059 inhibits the scattering response and
tubulogenesis in HGF/SF treated MDCK cells (Khwaja et al. 1998). Inhibition of MAP kinase
pathway with PD98059 also inhibits HGF/SF induced cell migration in mICD-3 cells (cells
20

derived from the inner medullary collecting duct) (Karihaloo et al. 2001). HGF/SF stimulates
MAPK signaling pathway in human hepatoma cells, and inhibition of ERK1/2 phosphorylation
by MEK inhibitor PD98059 or inhibition of ERK1/2 kinase activity by nonsteroidal antiinflammatory drugs aspirin and NS-398 suppresses HGF/SF-induced invasiveness of Hep2
human hepatoma cells (Abiru et al. 2002).
MAP kinase signaling pathway plays an important role in HGF/SF stimulation of
biological activities such as cell migration, morphological changes, and invasiveness in various
cell types. It has also been shown that TGFβ1 stimulates large conductance, Ca2+-activated K+
channel activity via activation of ERK MAP kinase in chick cilliary ganglions (Lhuillier and
Dryer 2000). Therefore, we propose that MAP kinase signaling pathway plays a role in HGF/SF
activation of Ca2+-activated K+ channel and migration in MDCK II cells.
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CHAPTER 2
MATERIAL AND METHODS

Cell Culture
Madin-Darby canine kidney epithelial (MDCK II) cells were maintained in 25-mm2 Tflasks with Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium (Sigma, St. Louis, MO),
which was supplemented with 5% fetal bovine serum (Atlanta Biologicals Inc., Norcross, GA),
100 I.U./ml penicillin, 100 µg/ml streptomycin (Sigma, St. Louis, MO). Cells were incubated in
a 95% air/5% CO2 in a water-jacketed tissue culture incubator. Medium was changed every
other day, and cells were passaged every 5-7 days. The latter consisted of washing the cells
twice with phosphate-buffered saline (PBS), incubating them 45-60 min with porcine trypsin
(1.2 – 2.5 mg/ml PBS), followed by pelleting of the suspended cells, aspirating the trypsin
solution, diluting with fresh complete medium, and replating the cells.

Reagents
Charybdotoxin, iberiotoxin, and stichodactyla toxin were obtained from Alomone
Laboratories (Jerusalem, Israel), and Accurate Chemical & Scientific Corporation (Westbury,
NY). Clotrimazole and PD98059 were obtained from Sigma (St. Louis, MO). Human HGF/SF
was obtained as a gift from Dr. G. F. Vande Woude, Van Andel Research Institute, Grand
Rapids, MI. HGF/SF concentrations are presented as scatter units/ml; five scatter units are
equivalent to approximately 1 ng of protein.

Antibodies
Neutralizing monoclonal antibodies to HGF/SF were obtained as gifts from Dr. G. F.
Vande Woude, Van Andel Research Institute, Grand Rapids, MI. Polyclonal antibodies to ERK
and phosphorylated ERK were obtained from Cell Signaling Technology (Beverly, MA).
22

Preparation of Microelectrodes
Borosilicate glass capillaries (1.2 mm OD, 0.68 ID, type EN-1, Garner Glass Co.,
Claremont, CA) were cleaned in a sonicator and dried in a convection oven at 90°C. Pipettes (38 MΩ in the bath solution) were fabricated from the capillaries with a Brown-Flaming horizontal
micropipette puller (P-87, Sutter Instruments, San Rafael, CA). Whole-cell pipettes were coated
to within 0.5 mm of the tip with polystyrene base coil dope (Polyweld 912, Amphenol,
Wallingford, CT); cell-attached pipettes were coated with R6101 to reduce the noise (Dow
Corning Corp., Midland, MI). The tips were heat-polished prior to use. A micromanipulator
(MO-202, Narishige, Tokyo) fixed to the microscope was used to position pipettes.

Whole-Cell and Cell-Attached Voltage Clamp Techniques
Cells were seeded on 4 × 4-mm sections of plastic coverslips for 24 hr before treatment
with various agents. After treatment the coverslips were transferred to an acrylic chamber
(Warner, New Haven, CT) on the stage of an inverted microscope (Olympus IMT-2, Melville,
NY) equipped with Hoffman modulation contrast optics. The whole-cell and cell-attached
configurations were obtained by standard patch clamp technique (Hamill et al. 1981).
Membrane currents were measured with a patch clamp amplifier (Axopatch 1-D, Axon
Instruments, Foster City, CA) with the lowpass, Bessell filtering (-3 dB) set at 2kHz. Whole-cell
currents from the patch clamp amplifier were fed into a DMA-1 digital interface connected to a
486-SX computer equipped with Clampex software (Axon Instruments). Records were stored on
an internal Jaz drive (Iomega, Roy, UT). Ag/AgCl half-cells constituted the electrodes, and an
agar bridge (4% w/v in external gluconate solution) connected the reference electrode to the bath
solution. The junction null was zeroed in the cell-attached mode prior to whole-cell access.
Electrode series resistances were measured following whole-cell access, and were compensated
prior to recording.
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Solutions Used for Patch Clamp
Cells for patch-clamp recording were superfused at room temperature with a standard
external salt solution, and gluconate was used to substitute for the Cl- in the solution. For wholecell patch clamp, pipettes were filled with standard internal solution, which was buffered with
EGTA to reach a free Ca2+ concentration of 28 nM, 1 µM or 7 µM according to G. Droogmans
(ftp://ftp.cc.kuleuven.ac.be/pub/droogmans/cabuf.zip). For cell-attached patch clamp, pipettes
were filled with standard external solution. The compositions of the solutions used through out
these experiments were given in Table 1.

Preparation of Transwell Membranes
Transwell polycarbonate membranes with a pore size of 8 µm were inserted into 24well cluster plates (Costar Corporation, Cambridge, MA). The bottom side of each membrane
was coated with 100 µl of fibronectin (25 µg/ml in sterile PBS; Sigma, St. Louis, MO). These
were rinsed twice with PBS, once with 1% w/v bovine serum albumin (BSA; Sigma, St. Louis,
MO) in PBS, and blocked with 1% BSA in PBS for 30 min at room temperature. The bottom
side of each control membrane was treated with 100 µl BSA (1% w/v in PBS) for 1 hour at room
temperature.

Transwell Cell Migration Assay
800 µl of migration assay buffer (containing serum-free DMEM/F-12, 0.1% BSA, 100
I.U./ml penicillin, 100 µg/ml streptomycin) was added to the lower chamber of each well.
Various agents and combinations were added to the lower chambers before moving the inserts
into the wells. The final concentration of these drugs was computed by assuming diffusion
equilibration with the 200 µl volume of medium added to the upper chambers. MDCK II cells
were harvested, washed in PBS, and suspended in migration assay buffer at a cell density of
24

3×105 cells/ml. 200 µl aliquots of cells were plated on the upper membrane surface of each
insert. The tissue culture plates were then returned to the tissue culture incubator for 8 hr.

Fixation, Staining and Counting of MDCK II Cells
After 8 hr incubation, inserts were rinsed, and cells on the upper membrane surface
were gently removed using cotton swabs. Cells on the under surface were fixed in 100%
methanol (10 min) at 4°C and stained for 15 min. with modified Harris hematoxylin solution
(Sigma, St. Louis, MO). Ten randomly selected fields of 0.6 mm2 were counted using an
inverted microscope (Olympus IMT-2, Melville, NY) to determine the number of cells that
migrated in the experimental groups and the untreated controls. Each experiment was repeated 3
times.

Protein Harvesting for Western Blotting
Cells were made quiescent by serum starvation for 24 hr followed by stimulation with
HGF/SF (100 scatter units/ml). For ERK inhibition studies, cells were pre-incubated with 50
µM PD98059 (Sigma, St. Louis, MO) for 30 minutes before the addition of HGF/SF. Cells were
lysed for 20 minutes on ice with ice-cold lysis buffer, which contained 50 mM Tris-HCl, 150
mM NaCl, 1% Triton X-100 [pH=8.0], 1 µg each of leupeptin, pepstatin, and antipain, 1 mM
sodium orthovanadate, 1 mM PMSF, 1 mM EDTA, and 1 mM NaF (Sigma, St. Louis, MO). The
extraction solutions were then centrifuged at 14,000 × g for 15 min at 4°C and the supernatants
were saved, and the protein contents were determined by the BCA assay.

Western Blotting Analysis of ERK
A protein sample (20 µg) from each extraction solution was separated on 12% SDS
PAGE and transferred to nitrocellulose membranes. The membranes were placed in the blocking
buffer (5% non-fat dry milk, 0.1% Tween20 in tris-buffered saline (TTBS)) for 1 hr, and
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subsequently incubated at 4°C overnight with 1:1000 diluted primary anti-total ERK and antiERK-P antibodies, respectively (Cell Signaling Technology, Beverly, MA). The membranes
were washed with TTBS for 15 minutes, 4 times, then incubated with secondary horseradish
peroxidase-conjugated goat anti-rabbit IgG antibody (1: 2000) for 1 hr at room temperature.
After two washes in TTBS, two washes in tris-buffered saline (TBS), 15 minutes each,
membranes were incubated with LumiGLO for 1 minute, and exposed to film. Densitometry
was performed using Intelligent Quantifier (Bio Image, Ann Arbor, MI).

Statistics
Results were given as mean ± SE. Student t-test, one-way analysis of variance, multiple
comparisons, and regression analysis were performed where applicable. Analysis of covariance and
t-test were performed to compare slope conductance. Slope conductance was obtained from the
regression analysis on the linear component (4 data points) of the I-V plots. Significant differences
among means or slope conductance were determined at P < 0.05.
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Table 1 Salt solutions used to fill bath and pipets.
Externa
l
(bath)

Externa
l
(hypo)

Externa
l
(hi K+)

Internal

Internal

(7 µM
[Ca2+]i)

(1 µM
[Ca2+]i)

Internal
(28 nM
[Ca2+]i)

Na gluconate
(mM)

135

95

0.4

-----

-----

-----

K gluconate
(mM)

5.4

5.4

140

140

140

140

CaCl2 (mM)

1.8

1.8

1.8

0.998

0.854

0.1

MgCl2 (mM)

2

2

2

2

2

2

EGTA (mM)

-----

-----

-----

1

1

1

Glucose (mM)

1

10

10

-----

-----

-----

HEPES (mM)

1

5

5

5

5

5

7.41

7.41

7.41

7.2

7.2

7.2

SOLUTIONS

PH
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CHAPTER 3
RESULTS

HGF/SF Stimulates Membrane Currents in MDCK II Cells
in A Time-Dependent Way
MDCK II cells formed discrete colonies of tightly juxtaposed cells when seeded on
coverslips. The cells scattered by spreading and migrating during 8 and 24-hr stimulation by
HGF/SF. These cells also were readily studied by patch clamp electrophysiology. Voltage
ramps from –100 to 50 mV (pipette potential) were applied in cell-attached configuration to
MDCK II cells treated with different concentrations of HGF/SF (10, 50 100 scatter units/ml) for
24 hr. Fig. 2 shows HGF/SF stimulated a membrane K+ current over 24 hr, and the stimulation
was more significant at higher dose of HGF/SF. There were also some inward currents activated
at around 50 mV (pipette potential) with higher doses of HGF/SF, which could be sodium
channels and need further study to characterize them.
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A. Untreated
0.5 s

60

Current (pA)

B. 10 units/ml HGF, 24 hr

20 pA

40
20
0
-20

D. 100 units/ml HGF, 24 hr

C. 50 units/ml HGF, 24 hr

Current (pA)

60
40
20
0
-20
-120

0

50

-120

0

50

Pipette Potential (mV)

Figure 2 HGF/SF stimulates membrane K+ current in MDCK II cells in cell-attached
configuration. Pipettes were filled with standard external solution with gluconate substitute for
Cl-. Cell-attached currents were recorded on voltage ramp from –120 to 50 mV (pipette voltage)
for a duration of 1.4 s. A. Cell-attached recording of an untreated MDCK II cell. B. Cellattached recording of an MDCK II cell treated with 10 scatter units/ml HGF/SF, 24 hr. C. Cellattached recording of an MDCK II cell treated with 50 scatter units/ml HGF/SF, 24 hr. D. Cellattached recording of an MDCK II cell treated with 100 scatter units/ml HGF/SF, 24 hr.
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Characteristics of Membrane Currents Stimulated by HGF/SF
in MDCK II Cells
In order to understand the characteristics of these K+ channels, whole-cell recordings
were performed with different free Ca2+ concentrations in internal solutions (pipette solution).
The mean ± SE value of pipette/membrane seal resistance was 5.8 ± 0.2 GΩ (n =112). The
corresponding measurements of whole-cell capacitance = 16.8 ± 0.7 pF; the series access
resistance = 7.2 ± 0.2 MΩ; and the whole-cell resistance = 170 ± MΩ.
Current-voltage (I-V) relationships that were obtained from data points taken at the end
of similar voltage pulses yielded continuous increases in membrane K+ conductance at 4 and 24
hr of HGF/SF treatment compared with control cells, Fig. 3. Voltage ramps from –100 to 100
mV were applied to an HGF/SF-treated cell (200 scatter units/ml for 24 hr), and the results are
shown in Fig. 4. This was done first under control conditions of 5.4 mM external [K+]; then the
voltage ramp was repeated after the cell was exposed to 140 mM external [K+], which was
symmetrical with the pipette [K+]; and then after switching back to control solution. The
increase in external [K+] resulted in a shift in current reversal potential from ≈ -60 mV to ≈ 5mV,
along with an increase in slope conductance. These reversed after switching back to the control
solution. Such responses of the HGF/SF-treated cell to the changes in external [K+] were
consistent with those expected of membrane K+ conductance.
To characterize the K+ channels activated by HGF/SF, intracellular free Ca2+ was
buffered at 28 nM, 1 µM or 7 µM for whole-cell recordings. MDCK II cells were treated with
200 scatter units/ml HGF/SF (for 24 hr) for whole-cell recording with 28 nM and 1 µM of
[Ca2+]i; whereas, the cells were treated with 50 scatter units/ml HGF/SF (for 24 hr) for wholecell recordings with 7 µM of [Ca2+]i. After obtaining the whole-cell currents recorded in the
control bath solution, the control solution was changed to a solution with 50 nM ChTX. Slope
conductance and reversal potentials (Vr) recorded under various conditions were compared in
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Table 2. ChTX (50 nM) had no effect on membrane K+ current at 28 nM or 1 µM [Ca2+]i in
untreated cells; however, it significantly inhibited membrane K+ current at 7 µM [Ca2+]i in these
cells. HGF/SF significantly increased slope conductance at 1µM [Ca2+]i (Fig. 6, right); it also
stimulated membrane K+ currents at near zero and positive membrane potentials at 7µM [Ca2+]i
(Fig. 8). ChTX (50 nM) significantly inhibited these increases stimulated by HGF/SF.
However, at 28 nM [Ca2+]i, ChTX (50 nM) had no effect on membrane K+ currents in HGF/SFtreated cells. Therefore, HGF/SF stimulation on membrane K+ current is regulated by
intracellular Ca2+ concentration.
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0.20

HGF (4 hr)
HGF (24 hr)

(nA/pF)

Control

0.10

-100

-50

50
(mV)

-0.10

Figure 3 HGF/SF stimulates membrane K+ current in MDCK II cells after 4 and 24 hr treatment.
HGF/SF concentration was at 200 scatter units/ml. Current-voltage (I-V) plot for whole-cell
currents recorded in MDCK II cells during voltage pulses ranging from –100 to 80 mV in
consecutive, 20 mV increments. (Mean±SE; n=3 cells).
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2
Washout = 5.4 mM K

+

1
Control = 5.4 mM K

-100

+

-50

50
100
Membrane Potential (mV)

Experimental =
+

Current (pA)
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Figure 4 Whole-cell currents recorded in an MDCK II cell on application of voltage ramp.
Voltage ramp was from –100 to 100 mV (1.5 s in duration). Control trace was recorded right
after break-in, experimental trace was recorded shortly after exchange of extracellular solution
with 140 mM K+ from a solution containing only 5.4 mM K+ (Control). Washout trace was
recorded after switching back to control solution.
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Table 2 Effects of ChTX (50 nM) on HGF/SF stimulation of membrane K+ current at
different intracellular [Ca2+]i.
[Ca2+]i

bath
solution

untreated

HGF/SF-treated

slope (nS/pF)

Vr (mV)

slope

Vr

control

0.24 ± 0.04
(n=4)

-55.9 ± 18.0
(n=4)

0.32 ± 0.08
(n=3)

-71.1 ± 10.9
(n=3)

ChTX

0.23 ± 0.05
(n=4)

-60.6 ± 21.2
(n=4)

0.26 ± 0.09
(n=3)

-64.3 ± 14.5
(n=3)

control

0.38 ± 0.05
(n=7)

-47.6 ± 3.5
(n=7)

0.79 ± 0.15
(n=7); !

-52.1 ± 4.5
(n=7)

ChTX

0.29 ± 0.06
(n=7)

-35.8 ± 4.1
(n=7)

0.30 ± 0.10
(n=7); *

-44.7 ± 3.8
(n=7)

control

0.90 ± 0.09
(n=5)

-100 ± 4.9
(n=5)

0.93 ± 0.16
(n=5)

-101.2 ± 3.5
(n=5)

ChTX

0.37 ± 0.09
(n=5); *

-76.8 ± 7.6
(n=5); *

0.33 ± 0.08
(n=6); *

-70.8 ± 6.9
(n=6); *

28 nM a

1 µM a

7 µM b

a. For [Ca2+]i of 28 nM and 1 µM, HGF/SF-treated MDCK cells were treated with 200 scatter
units/ml HGF/SF for 24 hr; b. for [Ca2+]i of 7 µM, HGF/SF-treated MDCK cells were treated
with 50 scatter units/ml HGF/SF for 24 hr.

!Significantly different from the same measurement in untreated cells (P < 0.05, refer to Fig.6,
right).
*Significantly different from the same measurement in control solution (P < 0.05).
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K+ Channel Blockers Inhibit HGF/SF-Stimulated Membrane K+ Currents
([Ca2+]i =1 µM) in MDCK II Cells
ChTX added at 50 nM for 5 min. inhibited membrane K+ current in MDCK II cells that
were treated with HGF/SF (200 scatter units/ml for 24 hr), Fig. 5. The I-V plots in Fig. 6
comprise summary results from repeated measurements of ChTX (50 nM) effects on untreated
(left), HGF/SF treated MDCK II cells at 100 (middle) and 200 scatter units/ml (right). ChTX
had no significant effect on slope conductance for K+ currents in untreated MDCK II cells
(ANCOVA, P > 0.05, n = 7 cells) or in cells treated for 24 hr with 100 scatter units/ml HGF/SF
(ANCOVA, P > 0.05, n = 3 cells). HGF/SF at 200 scatter units/ml significantly increased slope
conductance of membrane K+ current, which was inhibited by added ChTX at 50 nM
(ANCOVA, P < 0.05, n = 7 cells). IbTX also inhibited HGF/SF-stimulated membrane K+
currents in MDCK II cells. IbTX at 100 nM significantly decreased slope conductance of
membrane K+ current (ANCOVA, P < 0.05, n = 4 cells), along with a modest shift in reversal
potential toward 0 mV in MDCK II cells treated for 24 hr with 200 scatter units/ml of HGF/SF,
Fig. 7. CLT at 1 µM didn’t significantly inhibit HGF/SF-stimulated membrane K+ current in
MDCK II cells treated with HGF/SF (200 scatter units/ml, for 24 hr), the slope conductance in
control bath solution was 0.62 ± 0.18 (Mean ± SE, n=3 cells), the slope conductance in bath
solution with 1 µM CLT was 0.30 ± 0.07 (Mean ± SE, n=3 cells), paired t-test yielded a P >
0.05. Stk at 100 nM had no effect on HGF/SF stimulated membrane K+ current in MDCK II
cells treated with 200 scatter units/ml for 24 hr (data not shown).
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MDCK II Cell Treated with HGF/SF (200 scatter units/ml) for 24 hr.

Control

100 ms
0.5 nA

Charybdotoxin
(50 nM)

Figure 5 ChTX inhibits HGF/SF-stimulated membrane K+ current in an MDCK II cell. Wholecell currents were recorded during voltage pulses that ranged from -100 to 80 mV in consecutive,
20-mV increments. Holding potential = -50 mV. Left. MDCK II cell treated with 200 scatter
units/ml HGF/SF for 24 hrs in standard external solution with gluconate. Right. The same cell 5
min after 50 nM ChTX in the external solution.
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-0.05

*
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-0.05

* Slope differs from untreated, P<0.05

ChTX 50nM

Figure 6 Inhibitory effect of ChTX on HGF/SF stimulation over 24 hr of membrane K+ current
in MDCK II cells. Whole-cell currents were recorded during voltage pulses that ranged from 100 to 80 mV in consecutive, 20-mV increments. Holding potential = -50 mV. Left. Untreated
MDCK II cells (Mean±SE; n=7 cells). Middle. MDCK II cells treated with 100 scatter units/ml
HGF/SF for 24 hr (Mean±SE; n=3 cells). Right. MDCK II cells treated with 200 scatter units/ml
HGF/SF for 24 hr (Mean±SE; n=7 cells). *There is significant difference between the slope
conductance in control solution and in a solution with 50 nM ChTX.
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Figure 7 IbTX inhibits membrane K+ current in HGF/SF treated MDCK II cells. Whole-cell
currents were recorded during voltage pulses that ranged from -100 to 80 mV in consecutive, 20mV increments. Holding potential = -50 mV. (Mean±SE; n=7 cells). *There is significant
difference between the slope conductance in control solution and in a solution with 100 nM
IbTX.
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K+ Channel Blockers Inhibit HGF/SF-Stimulated Membrane K+ Currents
([Ca2+]i =7 µM) in MDCK II Cells
To further characterize the HGF/SF stimulation of membrane K+ current in MDCK II
cells, the inhibitor experiments were repeated at 7 µM internal [Ca2+], a concentration that was
sufficient for the activation of all types of Ca2+-activated K+ channels (Hille 2001). Fig. 8 shows
that HGF/SF (50 scatter units/ml) significantly stimulated membrane K+ currents at near zero
and positive membrane potentials in MDCK II cells (P<0.05, n=9 of untreated cells, n=9 of
HGF/SF-treated cells). Representative whole-cell current traces are shown in Fig. 9A (insert) for
comparison with those obtained from cells dialyzed with 1 µM [Ca2+]i, Fig. 4. Membrane
currents were greater at all voltages compared with measurements made with 1 µM internal
[Ca2+], and the corresponding I-V curves rectified inwardly, Fig. 9A-9D. K+ channel inhibitors
added for 5 min significantly reduced slope conductance of the whole-cell current in HGF/SFstimulated cells, ChTX (Fig. 9A), IbTX (Fig. 9B), Stk (Fig. 9C) and CLT (Fig. 9D). All these
inhibitors, except for CLT, also significantly reduced the reversal potential. ChTX (50 nM) also
significantly reduced slope conductance and reversal potential of the whole-cell K+ current in
untreated MDCK II cells at 7 µM internal [Ca2+] (not shown); however, CLT (1 µM) had no
effect. Fig. 10 shows the difference in the currents recorded from the control solution, and a
solution with a Ca2+-activated K+ channel blocker by deducting the inhibited current from the
control current in Fig. 9A-9D, respectively.
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Figure 8 Current-voltage plots recorded from untreated and HGF/SF-treated MDCK II cells.
Voltage steps were applied from –100 to 80 mV in consecutive, 20 mV increments. HGF/SF
treatment (50 scatterunits/ml for 24 h) stimulated membrane current at near zero mV and at
positive membrane potentials (n=9 of untreated cells, n=9 of HGF/SF treated cells).
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Figure 9 K+ channel blockers inhibit HGF/SF stimulated membrane K+ current in MDCK II
cells. [Ca2+]i was buffered to 7 µM. HGF/SF concentration was at 50 scatter units/ml. Currentvoltage (I-V) plot for whole-cell currents recorded in MDCK II cells during voltage pulses
ranging from –100 to 80 mV in consecutive, 20-mV increments. A. Effect of 50 nM ChTX on
HGF/SF treated MDCK II cells (n=5). The insert shows the representative traces of whole-cell
recording from an MDCK II cell under condition A. B. Effect of 100 nM IbTX on HGF/SF
treated MDCK II cells (n=3). C. Effect of 100 nM Stk on HGF/SF treated MDCK II cells (n=6).
D. Effect of 1 µM CLT on HGF/SF treated MDCK II cells (n=4). *There was significant
difference between the slope conductance in control solution. and in a solution with channel
inhibitor. (Mean ± SE; P < 0.5).
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Figure 10 Difference currents recorded from control solution and a solution with a channel
inhibitor. I-V curves were obtained by deducting the inhibited current from the control current
in Fig. 9A-9D, respectively.
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Effects of HGF/SF and K+ Channel Blockers on MDCK II Cell Migration
HGF/SF stimulated MDCK II cell migration in a dose-dependent manner, Fig. 11A.
Maximum stimulation occurred at 50 scatter units/ml of HGF/SF (8 hr) with no further increases
at higher concentrations. ChTX at 50 nM significantly inhibited stimulation of MDCK II cell
migration by HGF/SF at 100 scatter units/ml (Mean ± SE; P<0.05; n = 3), Fig. 11B. Fig. 11C
shows that CLT at 1 µM and Stk at 100 nM both significantly inhibited MDCK II cell migration
stimulated by HGF/SF at 100 scatter units/ml for 8 hr. The inhibition by ChTX increased with
dose, Fig 12. Here 25 scatter units/ml of HGF/SF stimulated MDCK II cell migration, and this
was inhibited with increasing concentrations of ChTX. However, 100 nM ChTX was necessary
for significant inhibition of this submaximal stimulation by HGF/SF. IbTX at 100 nM also
significantly inhibited migration in MDCK II cells treated with 25 scatter units/ml HGF/SF
(Mean ± SE; P<0.05, n = 3), Fig. 12.
HGF/SF has been shown to stimulate migration and metastasis of various normal and
malignant cells. Transwell migration assays were used to quantify the effects of HGF/SF and
other agents on MDCK II cell migration. Since a transwell migration assay took 8 hr,
hemacytometer experiments were used to determine whether HGF/SF had any effect on cell
proliferation during 8 hr, which may contribute to the cell count. Table 3 shows that there is no
difference between untreated and HGF/SF-treated cell counts after 8 hr incubation, and HGF/SF
doesn’t affect cell growth during 8 hr migration assays.
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Table 3 Hemacytometer experiments on MDCK II cells treated with or without HGF/SF
(100 scatter units/ml) for 8 hr.
Cell count at time 0
5

Cell count after 8 hr

Control cells

2×10 cells/petri dish

(1.8 ± 0.6)×105 cells/petri dish

HGF/SF treated cells

2×105 cells/petri dish

(1.9 ± 0.3)×105 cells/petri dish

*There was no significant difference between untreated and HGF/SF treated MDCK II cell
counts (n=5 petri dishes) after 8 hr treatment (Mean ± SE; P > 0.05).
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Figure 11 Effects of HGF/SF and K+ channel blockers on MDCK II cell migration. A. HGF/SF
stimulates MDCK II cell migration in transwell assays. MDCK II cells were treated with
different concentrations of HGF/SF for 8 hr. B. ChTX inhibits HGF/SF-stimulated MDCK II
cell migration. MDCK II cells were treated with 50 nM ChTX and/or 100 scatter units/ml
HGF/SF for 8 hr. C. CLT and Stk inhibit HGF/SF-stimulated MDCK II cell migration. MDCK
II cells were treated with 100 scatter units/ml HGF/SF alone, or with both HGF/SF and a channel
inhibitor for 8 hr. *Significantly different from HGF/SF treatment; **significantly different
from control (Mean ± SE; n = 3 inserts).
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Figure 12 ChTX and IbTX inhibit MDCK II cell migration treated with 25 scatter units/ml
HGF/SF. MDCK II cells were treated with HGF/SF and ChTX or IbTX for 8 hr in transwell
migration assay. *Statistically significant differences existed between cells treated with 25
scatter units/ml HGF alone and cells treated with HGF/SF plus 100 nm ChTX, or HGF/SF plus
100 nm IbTX. (Mean ± SE; n = 3 inserts).

46

ChTX Inhibits Hypotonic Stress-Induced Membrane K+ Current in MDCK II Cells
MDCK II whole-cell currents were recorded first under normosmotic conditions (Fig. 13,
left). Hypotonic stress, which was created by reducing external Na gluconate by 40 mM,
activated inwardly rectifying K+ currents that inactivated rapidly at positive voltages ≥ 60 mV
(Fig. 13, middle). This current activation reversed on restoring the control solution (Fig. 13,
right). Hypotonic stress increased the slope conductance of the membrane K+ current, and the
reversal potential shifted toward the EK of –85 mV. ChTX at 50 nM completely inhibited these
changes, Fig. 14A. However, IbTX (100 nM) failed to inhibit the hypotonic stress-activation of
membrane K+ current, Fig. 14B.
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Whole-Cell K Currents in a MDCKII Cell
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Figure 13 Hypotonic stress stimulates whole-cell currents in an MDCK II cell. Whole-cell
traces were recorded during voltage pulses ranging from –100 to 80 mV in consecutive, 20 mV
increments. Control, hypotonic, and washout currents were recorded in the same cell.
Hypotonic stress was created by reducing external Na gluconate concentration by 40 mM.
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Figure 14 Effects of ChTX and IbTX on hypotonic stress-induced membrane K+ current in
MDCK II cells. Current-voltage (I-V) plots for whole-cell currents recorded in MDCK II cells
during voltage pulses ranging from –100 to 80 mV in consecutive, 20 mV increments. A. Effect
of ChTX (50 nM) on hypotonic stress-induced membrane K+ current. B. Effect of IbTX (100
nM) on hypotonic stress-induced membrane K+ current. (Mean ± SE; n=3 cells).
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HGF/SF Stimulates ERK Phosphorylation in MDCK II Cells
It has been shown that HGF/SF stimulates the MAPK signaling pathway, which then
induces migration and morphological changes in various cell types. To demonstrate the effect of
HGF/SF on MAPK signaling pathway in MDCK II cells, the cells were treated with 100 scatter
units/ml HGF/SF from 5 min up to 24 hr, and western blotting analysis was performed on cell
extracts. Two 12% SDS gels were loaded identically, and probed with anti-total ERK and antiERK-P, respectively, Fig. 15A. Lane 1 was loaded with control non-phospho-ERK protein, and
lane 2 was loaded with control phospho-ERK protein. Two bands at 42 and 44 kDa were
revealed, standing for ERK2 and ERK1, respectively. HGF/SF treatment transiently increased
phosphorylation of ERK2, Fig.15A. Densitometry was performed to quantify the ratio of ERK-P
to total ERK. HGF/SF treatment significantly (P < 0.05) increased the ERK-P/ERK ratio at 5
min and 30 min, Fig. 15B. The stimulation diminished with further time, reaching the baseline
level after 8 hr.
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Figure 15 HGF/SF induces an immediate, but transient activation of phospho-ERK (ERK-P) in
MDCK II cells. MDCK II cells were cultured in the presence of 100 scatter units/ml HGF/SF
for various length of time as indicated. A. Representative blots of whole cell lysates separated by
12% SDS-PAGE and immunoblotted with anti-total ERK (upper panel) and anti-ERK-P (lower
panel). B. Normalized ERK-P/total ERK ratios from three independent experiments as shown in
A. (Mean ± SE; P < 0.05, n=3). *The ERK-P/ERK ratio of cells treated with HGF/SF for 5 min
or 30 min was significant different from the control ratio.
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MEK Inhibitor PD98059 Abolishes ERK Phosphorylation
in Untreated and HGF/SF-Treated MDCK II cells
PD98059 is a potent inhibitor of MAPK signaling pathway because it inhibits MEK
phosphorylation and the downstream cascade of MEK. Pretreating the MDCK II cells for 30
min. with the MEK inhibitor, PD98059 (50 µM), completely blocked the HGF/SF stimulated
increase in ERK phosphorylation, Fig. 16A. Fig. 16B shows that PD98059 abolished basal level
ERK phosphorylation in untreated MDCK II cells, as well as HGF/SF-stimulated ERK
phosphorylation in cells treated with HGF/SF for 5 min (Mean ± SE; P<0.05, n=3).
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Figure 16 PD98059 abolishes ERK phosphorylation in untreated and HGF/SF-treated MDCK II
cells. MDCK II cells were stimulated with HGF/SF (100-scatter units/ml) for 5 min with or
without pre-treatment of PD98059 (50 µM) for 30 min. Whole cell lysates were separated by
12% SDS-PAGE and immunoblotted with anti-total ERK (upper panel) and anti-ERK-P (lower
panel). A. Representative blots. B. Normalized ERK-P/ total ERK ratios from three
independent experiments as shown in A. *Significantly different from control. **Significant
different from HGF/SF treatment (Mean ± SE; P < 0.05, n=3).
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Neutralizing Monoclonal Antibodies to HGF/SF Inhibit HGF/SF-Induced
K+ Currents in MDCK II Cells
We have shown previously that HGF/SF added for 24 hr stimulates Ca2+-activated K+
currents in MDCK II cells. To determine whether the activation of membrane K+ currents in
HGF/SF-treated MDCK II cells is directly induced by HGF/SF, the neutralizing monoclonal
antibodies to HGF/SF (mAbs) were added to the culture medium immediately before the
addition of HGF/SF. Whole-cell patch clamp measurements were taken of MDCK II cells
untreated, treated with HGF/SF (50 scatter units/ml) alone, or HGF/SF plus the mAbs (at a molar
ratio of 1:20) for 24 hr. Fig. 17A shows the representative traces of whole-cell currents recorded
in response to voltage steps applied from –100 to 80 mV on an HGF/SF-treated cell and a cell
treated with HGF/SF and mAbs. Current-voltage (I-V) relationships, which were obtained from
repeated measurements as shown in Fig. 17A, are shown in Fig. 17B. As reported previously
(Fig. 2, 6, and 8), HGF/SF treatment for 24 hr significantly increased cell membrane K+
conductance. Compared to MDCK II cells treated with HGF/SF alone, the cells treated with
HGF/SF and mAbs had a significantly smaller slope conductance of membrane K+ currents
(Mean ± SE; P < 0.05, n=5 for both HGF/SF and HGF/SF + mAbs treated cells).
Untreated MDCK II cells were treated with or without mAbs to HGF/SF for 24 hr. The
results are shown in Fig. 17B. The difference in either the slope conductance or Vr between
untreated and untreated + mAbs MDCK II cells were not significant (P > 0.05, n=9 of untreated
cells, n=3 of untreated + mAbs cells). This suggests that neutralizing mAbs to HGF/SF did not
have effects on membrane K+ currents in untreated MDCK I cells.
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Figure 17 Neutralizing mAbs to HGF/SF block HGF/SF stimulation of membrane K+ current in
MDCK II cells. MDCK II cells were treated with HGF/SF (50 scatter units/ml) alone, or
HGF/SF+mAbs (at a molar ratio of 1:20) for 24 hr. A. Representative traces of whole-cell
currents recorded in response to voltage steps applied from –100 to 80 mV in consecutive, 20mV increments on an HGF/SF-treated cell (left) and a cell treated with HGF/SF and mAbs
(right). B. Current-voltage (I-V) relationships obtained from repeated measurements of four
treatments, untreated, untreated + mAbs, HGF/SF-treated, HGF/SF + mAbs treated. *Significant
difference between the slope conductance in HGF/SF-treated and HGF/SF + mAbs treated cells
(Mean ± SE; P < 0.05, n = 5). There was no significant difference in the slope conductance
between untreated and untreated + mAbs MDCK II cells.
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MEK Inhibitor PD98059 Inhibits HGF/SF-Induced Membrane K+ Currents in MDCK II Cells
MEK inhibitor PD98059 was used in the electrophysiological study to determine whether
the MAPK signaling pathway was involved in HGF/SF stimulation of membrane K+ currents in
MDCK II cells. The representative traces of whole-cell currents recorded in response to voltage
steps applied from –100 to 80 mV on an HGF/SF-treated (50 scatter units/ml) cell, a cell treated
with HGF/SF + DMSO (vehicle control, 0.26 % v/v), and a cell treated with HGF/SF + PD98059
(50 µM) were shown in Fig. 18A. Fig. 18B shows the current-voltage (I-V) relationships, which
were obtained from repeated measurements as shown in Fig. 18A. PD98059 (50 µM) significantly
inhibited HGF/SF-stimulated K+ current slope conductance in MDCK II cells (Mean ± SE; P<0.05,
n=5 cells). DMSO (0.26% v/v) had no effect on HGF/SF-stimulated K+ current slope conductance,
(Mean ± SE; P>0.05, n=5 cells). Because PD98059 inhibited basal level ERK phosphorylation as
well as HGF/SF-stimulated ERK phosphorylation in MDCK II cells, the effect of PD98059 on
membrane K+ currents was also studied in untreated MDCK II cells with added or without
PD98059 (50 µM for 24 hr). In untreated MDCK II cells slope conductance was 0.94 ± 0.11 nS/pF,
and the reversal potential (Vr) was –99.8 ± 4.4 mV (Mean ± SE, n=9 cells). Added PD98059
reduced slope conductance to 0.26 ± 0.01 nS/pF and decreased Vr to –74.3 ± 9.8 mV (Mean ± SE; P
< 0.05, n=3 cells).
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Figure 18 Effects of PD98059 and DMSO on membrane K+ current in HGF/SF-treated MDCK
II cells. MDCK II cells were pre-treated with PD98059 (50 µM) or DMSO (0.26% v/v) for 30
min before the addition of HGF/SF (50 scatter units/ml), and incubated for 24 hr. A.
Representative traces of whole-cell currents recorded in response to voltage steps applied from –
100 to 80 mV in consecutive, 20-mV increments on an HGF/SF-treated cell (left), a cell treated
with HGF/SF+DMSO (middle), and a cell treated with HGF/SF+PD98059 (right). B. Currentvoltage (I-V) plot of whole-cell currents obtained from repeated measurements as shown in A.
*Significant difference between the slope conductance in HGF/SF-treated cells and cells treated
with HGF/SF+PD98059. (Mean ± SE; P < 0.05, n=5 cells). There was no significant difference
between cells treated with HGF/SF, and those treated with HGF/SF+DMSO. (Mean ± SE; P >
0.05, n=5 cells).
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MEK Inhibitor PD98059 Inhibits HGF/SF-Induced MDCK II Cell Migration
To determine whether MEK inhibitor could affect HGF/SF stimulation of MDCK II cell
migration, PD98059 (50 µM) or DMSO (vehicle control, 0.26 % v/v) were added to the
migration assay buffer 30 min before the addition of HGF/SF (100 scatter units/ml) in the
transwell migration assay. Neutralizing mAbs to HGF/SF also were added to migration assay
buffer immediately before the addition of HGF/SF (molar ratio of HGF/SF to mAbs = 1:20).
Cells were then allowed to migrate for 8 hr. Fig. 19 shows the summary of the transwell
migration assays. Neutralizing mAbs to HGF/SF had no effect on untreated cell migration
(Mean ± SE; P > 0.05, n=3), but they significantly inhibited HGF/SF-treated cell migration
(Mean ± SE; P < 0.05, n=3). PD98059 (50 µM) significantly inhibited untreated cell migration,
as well as markedly inhibiting HGF/SF-stimulated cell migration (Mean ± SE; P < 0.05, n=3
inserts). DMSO alone (0.26 % v/v) also inhibited the HGF/SF-stimulated cell migration (Mean
± SE; P < 0.05, n=3 inserts). However, this inhibition of HGF/SF-stimulated migration was not
as great as that of PD98059.
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Figure 19 Effects of PD98059, DMSO, and neutralizing mAbs to HGF/SF on HGF/SFstimulated MDCK II cell migration. PD98059 (50 µM) and DMSO (0.26% v/v) were added to
the migration assay buffer 30 min before the addition of HGF/SF (100 scatter units/ml).
Neutralizing mAbs to HGF/SF (molar ratio of HGF/SF to mAbs=1:20)) were added to the buffer
right before the addition of HGF/SF. Cells were then allowed to migrate for 8 hr. (Mean ± SE;
n=3 inserts). *Significantly different from control cell migration (P < 0.05, n = 3 inserts).
**Significantly different from HGF/SF-treated cell migration (P < 0.05, n = 3 inserts).
#Significantly different from HGF/SF+PD98059 treated cell migration (P < 0.05, n = 3 inserts).
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CHAPTER 4
DISCUSSION

This research has demonstrated that HGF/SF stimulates cell migration as well as
membrane K+ currents in MDCK II cells. HGF/SF stimulation of the membrane K+ currents is
regulated by intracellular free [Ca2+]i. The various agents that block Ca2+-activated K+ channels,
the peptides ChTX, IbTX, and Stk along with CLT, inhibit both HGF/SF-stimulated cell
migration and membrane K+ current. Furthermore, we have observed that HGF/SF stimulates an
immediate, but transient activation of ERK phosphorylation in MDCK II cells, and MEK
inhibitor PD98059 abolishes ERK phosphorylation in untreated and HGF/SF treated cells. We
also have shown that neutralizing mAbs to HGF/SF and PD98059 both inhibit HGF/SF
stimulation of Ca2+-activated K+ channel and cell migration. Therefore, we conclude that 1) the
activation of Ca2+-activated K+ channel activation is necessary for HGF/SF-induced cell
migration; 2) MAPK ERK signaling pathway plays a role in HGF/SF-stimulated Ca2+-activated
K+ channel activation and cell migration in MDCK II cells.
The Ca2+-activated K+ currents activated by HGF/SF in MDCK II cells inactivate rapidly,
and, therefore, rectify inwardly, this resembles very much the intermediate conductance, Ca2+activated K+ channels (IK). Schwab and colleagues have demonstrated that the IK channel plays
a role in the migration of alkaline-transformed MDCK-F cells (Schwab et al. 1993, 1994).
Topical application of ChTX to the cell body inhibits MDCK-F cell migration (Schwab et al.
1997). It is proposed that migrating cells are polarized with K+ efflux dependent cell shrinkage
occurring in the cell body to facilitate retreat, and gelosmotic swelling occurs in the
lamellipodium providing membrane tension necessary to advance migration (Schwab 2001).
Thus, our present findings extend previous work by elucidating the mechanisms through which
HGF/SF affects the malignant transformation and the metastatic phenotype (Jeffers et al. 1996,
1996a, 1996b). We have shown that Ca2+-activated K+ channel blockers, ChTX, IbTX, Stk, and
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CLT, inhibit membrane K+ current and HGF/SF-stimulated cell migration. Thus, we proposed
that the inhibition of these channel inhibitors on HGF/SF-induced cell migration may be through
inhibition of local cell shrinkage, causing insufficient cell body contraction and retarded
migration in MDCK II cells treated with HGF/SF.
The doses of HGF/SF that stimulate MDCK II cell migration agree well with the doses
that stimulate outward-current channel activity using on-cell patch recording. Larger HGF/SF
doses (200 scatter units/ml) are necessary to activate whole-cell K+ current when the cells are
dialyzed with 1µM free intracellular Ca2+. However, HGF/SF at the concentration of 50 scatter
units/ml effectively stimulate K+ current at positive membrane potential when the cells are
dialyzed with 7 µM free intracellular Ca2+. Moreover, the Ca2+-activated K+ channel blockers
that inhibit HGF/SF-stimulated MDCK II cell migration also inhibit these whole-cell K+
currents. Taken together these findings suggest interplay between intracellular Ca2+ activation of
membrane K+ currents and the migration of MDCK II cells.
The intracellular [Ca2+]i needed for HGF/SF activation of membrane K+ current in
MDCK II cells is high by physiological standards. Notwithstanding, the intermediate
conductance, IK, and the high conductance, BK, Ca2+-activated K+ channels are thought to be
quite insensitive to [Ca2+]i with submicromolar amounts needed for IK and micromolar
concentrations needed for BK (Hille 2001). We have no basis to favor either IK or BK in
accounting for HGF/SF stimulation of either migration or membrane K+ current. Because the
inhibitors considered to be quite specific for the respective channels inhibited both variables, we
explain the relatively high [Ca2+]i needed for HGF/SF’s stimulation of K+ current by the
physiological kinetics of Ca2+-activated K+ current, which includes the diverse parameters that
regulate intracellular [Ca2+]i and the degree of colocalization of K(Ca) channels and the
intracellular sites of elevated [Ca2+]i.
HGF/SF causes oscillations of calcium activity in hepatocytes (Baffy et al. 1992; Kaneko
et al. 1992; Osada et al. 1992; Kawanishi et al. 1995) and oscillations of Ca2+-activated K+
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current in human gastric cancer cells (Liu et al. 1998). In this regard, migration of MDCK-F
cells depends on a ChTX-sensitive oscillation of Ca2+-sensitive 53-pS K+ channels (Schwab et
al. 1994). Oscillations of intracellular [Ca2+]i trigger opening of these channels, which result in
oscillations of membrane potential (Schwab and Oberliethner 1996). Moreover, migrating
MDCK-F cells demonstrate a horizontal gradient for intracellular [Ca2+]i with oscillations of
[Ca2+]i being greater in the cell body than in the lamellipodium (Schwab et al. 1997).
Gradients and oscillations of intracellular [Ca2+]i have been associated with local Ca2+
signaling called “puffs” in nonexcitable cells and “sparks” in excitable cells. These constitute
cytoplasmic Ca2+ microdomains that control local, apical secretion in acinar cells (Kidd et al.
1999), neurotransmitter release (Neher 1998), or neuronal growth (Spitzer et al. 2000), or they
may coalesce to form an intracellular Ca2+ wave that leads to myocyte contraction (Bootman et
al. 2001). In smooth muscle Ca2+ sparks activate BK channels in the membrane microdomain
that regulate membrane potential and voltage-gated channels (ZhuGe et al. 2000; Perez et al.
2001; Pozo et al. 2002). ZhuGe et al. have shown that in smooth muscle cells, BK channels are
activated when exposed to a mean [Ca2+] on the order of 10 µM during a Ca2+ spark, also the BK
channels are found to be at higher density at the spark site rather than uniformly distributed over
the membrane (ZhuGe et al. 2002). In a similar manner, migrating MDCK-F cells are polarized
cells that rely on Ca2+-activated K+ (IK) channels, which are more active in the rear of the cells
(Schwab et al. 1995) and are associated with the larger of the Ca2+ transients (Schwab et al.
1997). Moreover, topical applicaton of charybdotoxin to the cell body inhibits MDCK-F cell
migration (Schwab et al. 1997) and results in cell swelling (Schneider et al. 2000); whereas,
topical application of ionomycin to the cell body shrinks the cells (Schneider et al. 2000).
Ca2+-activated K+ channels are critical to regulatory volume decrease (RVD) in many cell
types (Pasantes-Morales and Morales-Mulia 2000). Both the K+ efflux-dependent cell shrinkage
in rear of the cells and the gelosmotic swelling in the lamellipodium are required for cells to
migrate (Schwab 2001). It has been proposed that ion channels and transporters modulate
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cytoskeletal migration machinery by regulating [Ca2+]i and local cell volume of migrating cells
(Schneider et al. 2000). Human melanoma cells that are devoid of the actin cross-linking protein
ABP280 are unable to volume-regulate or activate K+ channels when exposed to a hypotonic
stimulus. By transfecting with ABP280 these cells could migrate as well as regulate K+ channels
(Cantiello et al. 1993). However, migration of rescued melanoma cells is inhibited when Ca2+activated K+ channels are blocked (Cantiello et al. 1993).
Whole-cell recordings under hypotonic stress (with 1 µM [Ca2+]i) and 50 scatter units/ml
HGF/SF (with 7 µM [Ca2+]i) are both inwardly rectifying. Furthermore, ChTX inhibits
hypotonic stress-activated K+ currents, as well as HGF/SF stimulated cell migration in MDCK II
cells. This suggests that Ca2+-activated K+ channels may play a role in HGF/SF-stimulated
MDCK II cell migration via local cell volume regulation. However, IbTX inhibits HGF/SF
stimulated MDCK II cell migration and membrane K+ current, but fails to inhibit hypotonic
stress induced K+ current. This discrepancy may be explained that the subtypes of Ca2+activated K+ channels activated by HGF/SF are different from those activated by hypotonic
stress, and the binding specificity of ChTX and IbTX to these subtype channels also vary. Some
subtypes of Ca2+-activated K+ channels may be more prevalent in HGF/SF stimulated situation
than under hypotonic stress, whereas hypotonic stress may induce more complex and larger
channel activation than HGF/SF. Our recording also shows that HGF/SF stimulates an inward
current in MDCK II cells, which is likely to be Na+ current, further study is needed to
characterize these channels, and it may be very helpful to understand the effect of HGF/SF on
cell functions.
HGF/SF stimulates a transient activation of ERK phosphorylation, but the activation of
membrane Ca2+-activated K+ currents (over 24 hr) and cell migration (8 hr) are sustained for
much longer time. This can be explained as follows. Firstly, it takes a long time for the cells to
migrate through the pores and reach the bottom side of the inserts to be visualized under
microscope in transwell migration assay, which accounts in part for the time length of 8 hours in
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migration assay. Secondly, these data also suggest that the effects of HGF/SF on Ca2+-activated
K+ current require the transcription and synthesis of new proteins, rather than through
immediate, direct effects of the ligand. Western blotting using antibody to Slo α subunit of large
conductance, Ca2+-activated K+ channels (BK) shows that HGF/SF does not affect BK channel
expression in MDCK II cells (data not shown). It has also been shown that TGFβ1 stimulates
Ca2+-activated K+ channels by making new proteins that regulate channel activation rather than
channel proteins (Lhuillier and Dryer 2000). Hypotonic stress induces an immediately activation
(within 5 min) of inwardly rectifying K+ current in MDCK II cells, which is significantly
inhibited by ChTX (50 nM) in the bath solution. This indicates that the Ca2+-activated K+
channels are already in the cell and respond to the hypotonic stress quickly. Therefore, we
propose that HGF/SF stimulates the synthesis of new proteins that regulate Ca2+-activated K+
channels functions, rather than K+ channel proteins. The new proteins synthesized probably
interact with channels, modulate channel activity (via intracellular Ca2+ oscillation, channel
sensitivity to Ca2+, etc.), or recruit channels already in the cytoplasma of the plasma membrane.
MAPK signaling pathway has been shown to play an important role in HGF/SF
stimulation of scattering, migration and invasiveness in MDCK cells and other cell types. A
constitutively active ERK1 mutant and a stably dedifferentiated derivative (MDCK-C7F, which
expresses increased ERK2 activity) of MDCK-C7 cells assume elongated fibroblastoid shape
and high invasiveness (Montesano et al. 1999). We have shown that HGF/SF stimulates ERK2
phosphorylation, thus increases the ratio of ERK-P/total ERK in MDCK II cells. Nevertheless,
Schramek et al. have demonstrated that ERK1 protein expression and serum-induced ERK1
activation are greatly reduced in alkali-dedifferentiated MDCK-C7F cells; however, the ERK2
phosphorylation was substantially increased in these cells. This indicates an association between
the changes of ERK1 and ERK2. The inhibition of ERK1 expression and increased stimulation
of ERK2 might be involved in alkaline stress-induced dedifferentiation and/or growth –
inhibition of MDCK-C7F cells (Schramek et al. 1997). The specific MEK inhibitor PD98059
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inhibits the phosphorylation of MEK, thus inhibits the activation of ERK and other downstream
reactions in the cascade. We also demonstrated that PD98059 inhibits Ca2+-activated K+
channels and cell migration induced by HGF/SF, which suggests that MAPK signaling pathway
plays a role in HGF/SF stimulation of channel activation and cell migration.
Besides the inhibition on Ca2+-activated K+ channel activation by HGF/SF, PD98059
may also inhibit cell migration via cell-cell and cell-matrix interaction. It has been shown that
that activation of ERK phosphorylation is required for HGF/SF-stimulated scattering by causing
increased adherens junction proteins, and PD98059 inhibits both (Lu et al. 1998; Potempa and
Ridley 1998). ERK phosphorylation also has direct effects on cytoskeletal organization and cell
motility; it activates myosin light chain kinase (MLCK), which in turn regulates MLC and
myosin II formation in FG carcinoma cells (Klemke et al. 1997). Taken together, MAP ERK
signaling pathway modulates HGF/SF-stimulated cell migration by regulating local cell volume
via Ca2+-activated K+ channel, cell-cell, and cell-matrix interaction and direct effect on
cytoskeletal machine. Figure 18 shows the schematic model of the role of MAP ERK relating
Ca2+-activated K+ channels and cell migration in MDCK II cells.
In summary, HGF/SF is a multifunctional effector that stimulates morphological changes,
dissociation, scatter and migration of epithelial and other cell types. ChTX, IbTX, Stk, and CLT
all inhibit HGF/SF-stimulated membrane K+ current and migration in MDCK II cells. Therefore,
we propose that Ca2+-activated K+ channels play a role in HGF/SF-stimulated MDCK II cell
migration, and MAPK ERK signaling pathway is in part the cellular mechanisms relating Ca2+activated K+ channels and cell migration to HGF/SF in MDCK II cells. Met and/or HGF/SF
expression and over-expression have been observed in a variety of tumors. HGF/SF-stimulated
cell migration plays an important role in tumor invasiveness and metastasis. Therefore, the
dependence of HGF/SF-stimulated migration on Ca2+-activated K+ channels may provide a target
on the cell surface for therapeutic intervention for diseases in which cell migration contributes to
the pathology.
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Figure 20 Schematic model of the role of MAPK/ERK relating Ca2+-activated K+ channel
activation and cell migration in HGF/SF-treated MDCK II cells. Upon HGF/SF binding, Met
receptor are dimerized and activated. Ras is activated through Grb-Sos as indicated in Fig. 2,
then downstream Raf, MEK1/2, ERK1/2 are activated. ERK activation signals to the nucleus
and new regulatory proteins are synthesized, which then regulate Ca2+ channel, as well as Ca2+activated K+ channel. Ca2+ channel activation induces actinmyosin formation by elevating local
[Ca2+]. The activities of Ca2+ channel and Ca2+-activated K+ channel have two-way effects on
each other. K+ and H2O leave the rear of the cell upon Ca2+-activated K+ channel activation, thus
causing local shrinkage at the cell body. Both local cell shrinkage and actinmyosin formation
then facilitate cell migration by inducing the rear of the cell to contract.
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